Ann Marie Timmerman, Registered Nurse - Community Health Medicare: Not Enrolled in Medicare Practice Location: 44475 Aeolian Way, Neskowin, OR 97149 Phone: 707-954-8690 |
News Archive
Infusion of a combination therapy consisting of glucose, insulin, and potassium, which was thought could be a beneficial treatment immediately following a heart attack, may increase the risk of heart failure and death in the first 3 days for patients with ST-segment elevation myocardial infarction (STEMI; a certain pattern on an electrocardiogram following a heart attack), according to a study in the November 28 issue of JAMA: The Journal of the American Medical Association.
Alzheimer's disease is the leading cause of dementia in the U.S., with approximately 5.4 million currently affected and an estimated 16 million by 2050.
Chronic pain often goes unnoticed and therefore untreated in patients with cognitive impairments such as dementia. This was shown in a recent Slovenian study that was presented at the Congress of the European Academy of Neurology in Copenhagen.
AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treatment of progressive multiple sclerosis.
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.
› Verified 8 days ago